Efficiency and safety of five procedures for percutaneous native kidney biopsy: a multicentric comparative study. by bataille, stanislas et al.
HAL Id: hal-01313301
https://hal-amu.archives-ouvertes.fr/hal-01313301
Submitted on 18 Nov 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0
International License
Efficiency and safety of five procedures for percutaneous
native kidney biopsy: a multicentric comparative study.
Stanislas Bataille, Laurent Daniel, Jean Mondain, Magali Faure, Pierre
Gobert, Zarih Alcheikh-Hassan, Michel Lankester, Philippe Giaime, Jean
Gaudart, Yvon Berland, et al.
To cite this version:
Stanislas Bataille, Laurent Daniel, Jean Mondain, Magali Faure, Pierre Gobert, et al.. Efficiency and
safety of five procedures for percutaneous native kidney biopsy: a multicentric comparative study..
American Journal of Nephrology, Karger, 2012, 35 (5), pp.387 - 393. ￿10.1159/000337932￿. ￿hal-
01313301￿
Efficiency and safety of kidney biopsy 
1 
 
Original article 
 
Efficiency and safety of five procedures for percutaneous native kidney biopsy: a 
multicentric comparative study. 
Running title: Efficiency and safety of kidney biopsy 
Subject of manuscript: Renal pathology including clinicopathologic correlations 
 
Stanislas Bataille (1), Laurent Daniel (2), Jean-René Mondain (3), Magali Faure (3), Pierre 
Gobert (4), Zarih Alcheikh-Hassan (4), Michel Lankester (5), Philippe Giaime (6), Jean 
Gaudart (7), Yvon Berland (1), Stéphane Burtey (1) 
 
 
(1) Aix-Marseille Univ, 13284, Marseille, France, APHM, Hôpital de la Conception, Centre 
de néphrologie et transplantation, 13005, Marseille, France. 
(2) Aix-Marseille Univ, 13284, Marseille, France, APHM, Hôpital de la Timone, 
Laboratoire d'Anatomie Pathologique et Neuropathologie, 13005, Marseille, France.  
(3) Service de néphrologie, Hôpital Font Pré, 1208 avenue Colonel Picot BP 1412 Toulon 
Cedex. France 
(4) Service de néphrologie, Hôpital Général Henri Duffaut, Rue Raoul Follereau 84902 
Avignon Cedex. France 
(5) Service de néphrologie, Clinique La Résidence Du Parc, Rue Gaston Berger 13010 
Marseille, France. 
(6) Service de néphrologie, Clinique Bouchard, Rue du Docteur Escat, 13006 Marseille, 
France. 
(7) Aix-Marseille Univ, LERTIM EA3283, 13005, Marseille, France; APHM, Hôpital de 
la Timone, UF Biostatistiques, 13005, Marseille, France. 
Efficiency and safety of kidney biopsy 
2 
 
 
 
Corresponding authors:  
Stanislas Bataille, MD 
Service de néphrologie 
Hôpital de La Conception 
147 Boulevard Baille 
13005 Marseille, France 
Tel : +33 (0)4 91 38 30 42 
Email: stanislas.bataille@ap-hm.fr 
 
Stéphane Burtey, MD-PhD 
Service de néphrologie 
Hôpital de La Conception 
147 Boulevard Baille 
13005 Marseille, France 
Tel : +33 (0)4 91 38 30 42 
Email : stephaneb@ap-hm.fr 
Word Counts: 
 Abstract: 250 words 
 Article: 2577 words 
 
 
Efficiency and safety of kidney biopsy 
3 
 
 
Abstract 
Background and objectives 
Renal biopsy(RB) is necessary for the diagnosis, prognosis, and therapy guidance of native 
kidney diseases. Few studies have compared outcomes of RB procedures. We compared the 
efficiency and safety of five biopsy procedures. 
Design, setting, participants, and measurements 
Number of glomeruli on light microscopy(LM) and on immunofluorescence(IF) and serious 
adverse events following RB performed in five nephrology units(C1-C5) were retrospectively 
collected. 
C1 performed ultrasound assessment before RB and used a 14-gauge core-cutting needle 
biopsy gun, C2 ultrasound guidance and a 14-gauge needle, C3 tomodensitometry guidance 
and a 14-gauge needle, C4 ultrasound guidance and a 16-gauge needle, and C5 
tomodensitometry guidance and a 16-gauge needle. 
Results 
Data from 943 RB performed between January 2006 and July 2010 were collected (C1: 408; 
C2: 254; C3: 81; C4: 136; C5: 64). On LM, mean number of glomeruli on biopsy core was 
14.2±8.6. It was higher in C1 and C2 than in C3, C4, and C5(p=0.01). At least 10 glomeruli 
were found in 69% of biopsies. This rate was higher in C1 and C2 than in C3, C4, and 
C5(p=0.004). On IF, mean number of glomeruli was 4.4±3.3. It was higher in C1 and C2 than 
in C3, C4, and C5(p<0.001). In multivariate analysis, the only factor that influenced number 
of glomeruli on LM(p=0.004) and IF(p=0.004) was the nephrology unit. Serious adverse 
events occurred in 1.5% of biopsies. Complication rate was not different between nephrology 
units. 
Conclusions 
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RB is safe but radiological guidance, needle-size, and experience influence the quality of 
biopsies. 
 
Keywords: Renal biopsy; Procedure; Efficiency; Glomerular disease 
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Introduction  
Renal biopsy (RB) is necessary for the diagnosis, prognostic assessment, and therapy 
guidance of various diseases affecting native kidneys or transplants. Percutaneous native 
kidney RB procedures vary widely among nephrology units according to personal experience 
and availability of particular techniques (1). The gold-standard procedure should maximize 
the yield of tissue sampled and minimize the risk of major hemorrhagic complications. 
Three techniques are currently used for radiological guidance: real-time ultrasonographic 
(US) guidance, US assessment before RB, and tomodensitometry. These procedures are 
respectively used in 67%, 26%, and 6% of the French nephrology units (1). Biopsy-core 
needle size varies from 12 to 18 gauge; 16 gauge is the most used (58.3% of nephrologists) 
(1). 
Procedures might influence renal core size, which is critical for diagnosis. Clearly, having 
many tissues and glomeruli is diagnostically useful (2). To our knowledge, few studies have 
been published on the efficiency of RB procedures in adults (3, 4, 5). The gold standard for 
RB procedures remains to be defined. 
As an invasive procedure, RB also incurs potential bleeding complications of variable severity 
from transitory gross hematuria or pauci symptomatic hematoma to massive bleeding 
requiring nephrectomy and, very rarely, death (6, 7, 8). Although several studies have 
revealed risk factors associated with bleeding (9, 10, 11), it remains unknown which 
procedure best prevents complications. 
Our study compares the efficiency and safety of five native kidney percutaneous biopsy 
procedures in five nephrology units. 
 
Materials and Methods  
Patients 
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Data from percutaneous native kidney biopsies performed between January 2006 and July 
2010 in five nephrology units in the south of France were retrospectively collected. We 
recorded age at biopsy, gender, number of glomeruli on light microscopy (LM), number of 
glomeruli on immunofluorescence (IF), histopathological diagnosis, and the occurrence of 
any serious adverse event following renal biopsy. A serious adverse event was defined as 
bleeding requiring transfusion (hematoma or hematuria), arteriovenous fistula requiring 
embolization, pneumoperitoneum or urinoma, nephrectomy for bleeding or death. 
 
Renal biopsy procedures 
The five nephrology units named C1 to C5 consisted of one teaching hospital (C1), two public 
general hospitals, and two private centers. The RB procedures of these units are reported in 
table 1. All the units gave the patients oral and written information on the procedure and risks 
of the RB. Only one of the five units did not require written consent. 
In C1, oral and written information and consent was collected. Assessment of hemorrhagic 
risk factors before RB consisted of oral questioning about personal bleeding history, blood 
cell count, coagulation tests, and bleeding time. Nephrologists did not perform biopsy if 
systolic blood pressure was higher than 150 mmHg or if diastolic blood pressure was higher 
than 90 mmHg. No sterile urinalysis was required. The biopsy was performed by a senior or 
junior nephrologist. Radiological guidance was performed with ultrasound assessment before 
RB. Two biopsy cores were taken with a 14-gauge core-cutting needle automated side-notch 
biopsy gun. Patients were monitored during 24 h in hospital lying in bed.  
In C2, assessment of hemorrhagic risk factors was the same as in C1 except that blood 
pressure control required was less stringent, i.e. ≤160/95 mmHg. C2 was the only unit in 
which radiologists but not the nephrologists performed the kidney biopsy. The sampling was 
performed with US guidance: US was performed during the biopsy. As in C1, two fragments 
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were taken with a 14-gauge core-cutting needle automated biopsy gun and patients were 
monitored during 24 h lying in bed. 
In C3, the same hemorrhagic risk factors were assessed except bleeding time, which was not 
required. Blood pressure control was ≤140/90 mmHg. Kidney biopsies were performed by the 
nephrologists with tomodensitometry guidance. Two fragments were taken with a 14-gauge 
needle automated biopsy gun. Patients were monitored 24 h in hospital after biopsy as in all 
other units. 
In C4, nephrologists performed biopsy with US guidance like the radiologist in C2. The 
automatic biopsy gun needle was 16 gauge, which is smaller than in C1, C2, and C3. Two 
fragments were systematically taken: one for light microscopy and one for 
immunofluorescence. Only coagulation tests and oral bleeding history were checked but not 
blood cell count, urinalysis, or bleeding time. Blood pressure was required to be ≤140/90 
mmHg before biopsy and patients stayed in bed for 24 h hospital monitoring. 
In C5 as in C3, the nephrologists performed kidney biopsy under tomodensitometry guidance. 
Two fragments were taken with a 16-gauge needle automatic biopsy gun as in C4. Blood cell 
count, coagulation tests, and bleeding time were performed before biopsy and blood pressure 
≤150/90 mmHg was required. C5 was the only unit requiring urinalysis before biopsy. As in 
all the previous units, patient stayed in bed for 24 h in hospital. 
 
Laboratory biopsy analysis 
One fragment was taken for light microscopy (LM) and the other for immunofluorescence 
(IF). For LM, tissue was fixed in 2.5% glutaraldehyde for 12 h and embedded in araldite. 
Serial sections of 2 and 0.25 µm were stained respectively with Masson’s trichrome and Jones 
staining. Glomeruli were counted only if the whole glomerulus was present on the specimen. 
Material for IF was fixed in Michel’s liquid for 24-48 h and then frozen in -80°C isopentane. 
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Sections of 5µm were used for IF with fluorescein-conjugated antibodies specific for human 
IgG, IgM, IgA, C3, C1q, and kappa and lambda light chains. Glomeruli on frozen sections 
were counted excluding sclerosed glomeruli. During the study, all biopsies were read by the 
same pathologist. When no glomeruli were available, the biopsy was considered to have 
failed. In most glomerulopathy classifications, at least 10 glomeruli are required to consider 
the core biopsy representative and the diagnosis accurate (12, 13, 14). Thus, on LM analysis, 
biopsies were separated into three groups according to the number of glomeruli on tissue 
fragments: 0 glomeruli, 1 to 9 glomeruli, and 10 glomeruli or more. On IF analysis, because 
the number of glomeruli is less critical, biopsies were separated into only two groups: those 
with glomeruli and those with no glomeruli. 
 
Statistical Analysis 
For univariate analysis, mean comparisons were tested using analysis of variance (or Kruskall 
Wallis test if necessary). Relationships between qualitative variables were assessed using 
Pearson Khi² (or Fisher exact test if necessary). Relationships between quantitative variables 
were assessed using Pearson correlation coefficient (or Spearman approach if necessary). For 
multivariate analysis, logistic regression assessed covariates associated to LM and IF. P-
values were interpreted with a risk =0.05. The PASW® 17.0.2 (SPSS Inc.) software was 
used for statistical analysis.  
 
Results  
Efficiency of renal biopsy procedures 
Data from 943 native kidney RB were collected (C1: 408; C2: 254; C3: 81; C4: 136; C5: 64). 
Of them, 534 (57%) were men. Sex ratio was not different between the five nephrology units 
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(p=0.053). Mean age at biopsy was 52.8±19.7 (mean ±SD) years old (Table 2). It was 
statistically higher in C2 (57.2 ±20.0 years old) than in the other units (p<0.001). 
On LM, mean number of glomeruli on biopsy core was 14.2 ±8.6 (mean ±SD). It was 
statistically higher in C1 (15.1 ±9.1) and C2 (14.3 ±8.3) than in C3 (12.3 ±9.5), C4 (12.7 
±7.3), and C5 (13.3 ±7.4) (p=0.01). The number of biopsies with at least 10 glomeruli on LM 
was 651/943 (69%). It was higher in C1 (72%) and C2 (71%) than in C3 (57%), C4 (63%), 
and C5 (67%) (p=0.004) (Figure 1A). 
On IF, mean number of glomeruli on biopsy core was 4.4 ±3.3 (mean ±SD). As for LM, mean 
number of glomeruli was higher in C1 (5.2 ±3.8) and C2 (4.4 ±2.9) than in C3 (2.7 ±2.9), C4 
(3.6 ±2.4), and C5 (3.6 ±2.7) (p<0.001) (Figure 1B).  
Number of failed biopsies was 48/943 (5%) on LM. This rate was higher in C1 (8%) and C3 
(9%) than in the other units (p<0.001). Number of failed biopsies on IF was 99/943 (10%). It 
was higher in C3 (33%) than in the other nephrology units (p<0.001). Causes of failure are 
classified in two categories: medullary core with no glomeruli or no kidney core (Table 3). 
Renal diseases were nephroangiosclerosis (14%), IgA nephropathy (10%), minimal change 
nephropathy (9%), extracapillary glomerulonephritis (9%), lupus nephropathy (9%), focal and 
segmental glomerular sclerosis (8%), membranous glomerulonephritis (8%), interstitial 
nephritis (6%), diabetic nephropathy (4%), amyloidosis (3%), membranoproliferative 
glomerulonephritis (2%), others (14%), and no diagnosis (4%). Histology influenced the 
mean number of glomeruli on LM (p=0.001) and IF (p=0.015) in univariate analysis, but this 
effect was not found in multivariate analysis (p=0.4 and p=0.3). 
In univariate analysis, the numbers of glomeruli on LM analysis and on IF analysis were 
correlated with a correlation coefficient (CC) of 0.306 (p<0.001). Age was inversely 
correlated to number of glomeruli on LM (CC= -0.107; p=0.001) and to number of glomeruli 
in IF (CC= -0.086; p=0.005). Number of glomeruli on LM was higher in women (15.5+/-9.0; 
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mean ±SD) than in men (13.2±8.2) (p<0.001). On IF analysis, gender did not affect number of 
glomeruli, which was identical (4.4+/-3.3) in men and in women (p=0.8). 
In multivariate analysis, the only factor that significantly influenced number of failed biopsies 
on LM (p=0.004) and IF (p=0.004) was the nephrology unit. 
 
Safety of renal biopsy procedures 
Serious adverse events occurred in 14/943 (1.5%) of biopsies (Table 4). No nephrectomy or 
death was reported. Complication rate did not differ with nephrology unit (p=0.7), age 
(p=0.3), or gender (p=1). 
 
Discussion 
Most nephrologists perform renal biopsy by a standard technique developed in the early 1990s 
with an automated biopsy device and radiological guidance (15). Its superiority over previous 
techniques has been validated (5). Many options remain possible for radiological guidance 
techniques, and core-cutting needle size may vary between 14 and 18 gauge. Moreover, the 
precautions taken before and after biopsy vary according to nephrology units (16). In our 
retrospective study of 943 kidney biopsies comparing five different practices, we found no 
difference concerning severe complications according to biopsy procedure, but the choice of 
the procedure may affect biopsy efficiency. 
The practices in our study are representative of daily practices in nephrology units in France 
(1). Within the five nephrology units, all gave oral and written information prior to biopsy 
concerning indication, technique, monitoring, and recommended post-procedure precautions 
or potential complications. Four out of five units obtained written consent for RB. Bollée et 
al. reported 56% of units in France gave oral and written information and only 44% of units 
obtained written consent (1). Assessment of hemorrhagic risk factors before RB included oral 
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questioning about personal history of bleeding, blood cell count, and coagulation tests 
(prothrombin time and activated partial prothrombin time) in all units, but none obtained 
written questioning about personal history of bleeding. Differences appeared regarding 
bleeding time, which was recorded in only two units, and in platelet function analyzer 
(PFA100), recorded in one unit. Two units reported neither bleeding time nor platelet function 
analyzer. In all of France, 100% of nephrologists perform coagulation tests, 98% blood cell 
count, 76% oral questioning about personal history of bleeding, 57% bleeding time, and 11% 
PFA100 (1). Units C3 and C4 were stringent with hypertension whereas C2 tolerated 
hypertension of 160/95. In the literature, it remains controversial whether hypertension 
increases hemorrhagic risk (7, 9, 17). All of our patients were hospitalized for 24 h after 
biopsy. Whittier et al. reported a 33% risk of bleeding occurring 8 h after biopsy and an 11% 
risk of bleeding more than 24 h after biopsy (17). 
 
When minimal precautions are taken (blood cell count, coagulation test, no uncontrolled 
hypertension), RB is safe whatever the procedure used. In our “real-life practices” study, we 
found an overall serious adverse event rate of 1.5%, which is consistent with previously 
reported rates (7, 16). In the literature, serious complication following renal biopsy ranges 
from 0 to 7.7% (18). This rate is higher using Tru-Cut device instead of automated biopsy gun 
(19, 20), which explains why Tru-Cut is now abandoned. In a retrospective study of 5832 
renal biopsies, Atwell et al. reported an overall complication rate of 0.6%, which did not 
differ whether the patient was treated by aspirin or not at biopsy (21). Similarly, in our study, 
no difference was found between nephrology units. Thus, RB complication remains rare and 
technical procedure does not affect the rate of serious complications. Nevertheless, techniques 
might influence the efficiency of the kidney biopsy. 
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Number of glomeruli is critical for interpretation and classification of nephropathy in 
numerous international classifications. At least 10 glomeruli are recommended to provide an 
accurate diagnosis and prognosis based on RB (12, 13, 14). According to the literature, mean 
numbers of glomeruli on biopsies vary between 9 and 33 (18) according to needle size (19, 
20). In C1 and C2, the mean number of glomeruli and the proportion of kidney biopsies with 
more than 10 glomeruli were higher than in the other units. Two explanations can be given. 
First, C1 and C2 used 14-gauge core-cutting needles. In the literature, size of the needle 
influences the mean number of glomeruli on biopsies (2) and logically, 14-gauge needles 
provide more glomeruli on biopsy. Nevertheless, C3 also used 14-gauge needles, but had the 
lowest number of glomeruli on biopsies. The second explanation is that the two units (C1 and 
C2) who had the highest number of glomeruli on renal core on LM and IF are the two units 
performing the most biopsies. Thus, experience of biopsy may be critical for RB efficiency. 
Interestingly, C1 had a high mean number of glomeruli and successful biopsies but also a high 
rate of failed biopsies. 
In our overall population, biopsy failed on LM and IF in respectively 5 and 10% of biopsies. 
Reported rates of failed biopsy range between 0 and 6% (22, 18, 6). Scheckner et al. reported 
a 10.7% rate of inconclusive renal biopsies, including 1.5% with no kidney core available in a 
pediatric population (23). In our study, the number of failed biopsies was higher in C1 and 
C3. What is remarkable in these two units is that failed biopsies are mainly due to the absence 
of renal core and not to medullar sampling. The absence of kidney sample is certainly due to 
imprecise kidney localization. Thus, practices could be improved, especially in C1 where 
radiological guidance technique is US assessment before RB and not real-time guidance. This 
is supported by the findings of Maya et al., who showed that US guidance was more efficient 
than US previous assessment before RB (5). The high rate of failure in C1 might also be 
explained by a lack of experience, since it is a teaching nephrology unit. 
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Limitations of this study are retrospective data recording, lack of report of minor (but 
frequently not clinically relevant) complications, and absence of one-day procedure 
comparison. However, for native kidney, full hospitalization is the main procedure in France 
and worldwide (1). The 24 h follow up after procedure is important regarding the 20% rate of 
complications occurring between the 8th and the 24th hour following RB (17). 
 
In conclusion, renal biopsy is safe, with an overall serious adverse event rate of 1.5% 
whatever the procedure used. The quality of biopsies is influenced by radiological guidance, 
core-cutting needle-size, and experience. We propose that real time US guidance, a 14-gauge 
core-cutting needle automatic biopsy device, and good operator experience should be 
considered as the gold standard for native kidney biopsy. 
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Tables and figures 
 
Table 1: Kidney biopsy protocols in each of the nephrology units. 
 
Table 2: Demographic data, efficiency and complications of renal biopsies.  
 
Table 3: Number of renal biopsy failures on light microscopy and immunofluorescence 
according to the cause of failure. 
 
Table 4: Serious adverse events following renal biopsies according to nephrology unit. 
 
Figure 1: Number of glomeruli in biopsy core on light microscopy (LM) and 
immunofluorescence (IF) according to nephrology unit. 
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 C1 C2 C3 C4 C5 
Information 
Consent 
Oral and written 
Written 
Oral and written 
Oral 
Oral and written 
Written 
Oral and written 
Written 
Oral and written 
Written 
Precautions 
BH oral questioning 
BH written questioning 
Blood cell count 
Coagulation test* 
Bleeding time 
Urinalysis 
Blood pressure control 
 
Yes 
No 
Yes 
Yes 
Yes 
No 
≤150/90 
 
Yes 
No 
Yes 
Yes 
Yes 
No 
≤160/95 
 
Yes 
No 
Yes 
Yes 
No 
No 
≤140/90 
 
Yes 
No 
No 
Yes 
No 
No 
≤140/90 
 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
≤150/90 
Radiological guidance 
technique 
US assessment before 
RB 
Real-Time US 
guidance 
Tomodensitometry 
guidance 
Real-Time US 
guidance 
Tomodensitometry 
guidance 
Procedure 
Biopsy performer 
Device 
Core-cutting needle size 
Number of biopsy cores 
 
Nephrologist 
Automated biopsy gun 
14 gauge 
2 
 
Radiologist 
Automated biopsy gun 
14 gauge 
2 
 
Nephrologist 
Automated biopsy gun 
14 gauge 
2 
 
Nephrologist 
Automated biopsy gun 
16 gauge 
2 
 
Nephrologist 
Automated biopsy gun 
16 gauge 
2 
Monitoring after biopsy 24 h in hospital lying 
in bed 
24 h in hospital lying 
in bed 
24 h in hospital lying 
in bed 
24 h in hospital lying 
in bed 
24 h in hospital lying 
in bed 
 
Table 1: Kidney biopsy protocols in each of the nephrology units. 
BH: Bleeding personal history. * Coagulation test includes prothrombin time and activated partial prothrombin time. 
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 TOTAL C1 C2 C3 C4 C5 p 
Number of biopsies 943 408 254 81 136 64  
Number of men 534 (57%) 217 (53%) 146 (58%) 41 (51%) 87 (64%) 43 (67%) 0.053 
Age at biopsy in years (mean ±SD) 52.8 ±19.7 50.3 ±13.3 57.2 ±20.0 54.1 ± 21.3 52.2 ±19.5 51.1 ±15.9 <0.001 
Mean number of glomeruli on LM (mean ±SD) 14.2 ±8.6 15.1 ±9.1 14.3 ±8.3 12.3 ±9.5 12.7 ±7.3 13.3 ±7.4 0.01 
Mean number of glomeruli on IF (mean ±SD) 4.4 ±3.3 5.2 ±3.8 4.4 ±2.9 2.7 ±2.9 3.6 ±2.4 3.6 ±2.7 <0.001 
Number of biopsies on LM with (%): 
0 glomeruli 
1 to 9 glomeruli 
≥ 10 glomeruli 
 
48 (5%) 
244 (26%) 
651 (69%) 
 
32 (8%) 
81 (20%) 
295 (72%) 
 
3 (1%) 
70 (28%) 
181 (71%) 
 
7 (9%) 
28 (34%) 
46 (57%) 
 
4 (3%) 
46 (34%) 
86 (63%) 
 
2 (3%) 
19 (30%) 
43 (67%) 
 
<0.001 
 
 
Number of biopsies with 0 glomeruli on IF (%) 99 (10%) 37 (9%) 16 (6%) 27 (33%) 13 (10%) 6 (9%) <0.001 
Number of biopsies with serious adverse events 14 (1.5%) 7 (1.7%) 3 (1.2%) 1 (1.2%) 1 (0. 7%) 2 (3.1%) 0.683 
 
Table 2: Demographic data, efficiency and complications of renal biopsies. SD: standard deviation. LM: light microscopy. IF: 
immunofluorescence. 
 
 
0.004 
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 All C1 C2 C3 C4 C5 
 Light Microscopy 
No kidney core* 33 (69%) 26 (81%) 0 (0%) 6 (86%) 0 (0%) 1 (50%) 
Medullary 15 (31%)  6 (19%) 3 (100%) 1 (14%) 4 (100%) 1 (50%) 
Total 48 32 3 7 4 2 
 Immunofluorescence 
No kidney core* 44 (44%) 22 (59%) 4 (25%) 15 (55%) 0 (0%) 3 (50%) 
Medullary 55 (56%)  15 (41%) 12 (75%) 12 (45%) 13 (100%) 3 (50%) 
Total 99 37 16 27 13 6 
 
Table 3: Number of renal biopsy failures on light microscopy and immunofluorescence 
according to the cause of failure. * No kidney core includes no core available for 
histopathology or extra-renal tissue. 
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C1 
 
 
3 Arteriovenous fistula with embolization 
4 Hematoma with transfusion 
C2  
2 Arteriovenous fistula with embolization 
1 Hematoma with transfusion 
C3  
1 Hematoma with transfusion 
C4  
1 Arteriovenous fistula with embolization 
C5  
1 Pneumoperitonitis 
1 Urinoma 
 
Table 4: Serious adverse events following renal biopsies according to nephrology unit.   
 
 
 
 
 
